Shilpa Medicare announces positive outcome of Phase 3 studies of NorUDCA

Nor UDCA is likely to be a first-in-class treatment option for NAFLD in India

Sun Pharma introduces STARIZO in India for skin infections

Sun Pharma has obtained rights from MSD to develop, manufacture and commercialise Tedizolid Phosphate in India

Allozymes partners with Adisseo on next-gen animal feed production

Aptar’s nasal unidose system delivers FDA-approved neffy

This marks the first regulatory approval worldwide for nasally-delivered epinephrine

Imfinzi approved in the US for the treatment of resectable non-small cell lung cancer

Based on AEGEAN Phase III trial results which showed Imfinzi-based regimen reduced the risk of recurrence, progression or death by 32% vs. neoadjuvant chemotherapy alone

ICMR and Panacea Biotec initiates Phase III clinical trial of DengiAll

The clinical trial will be conducted at 19 sites with 10,335 participants across India

Wockhardt Q1 FY25 revenue up 14%

EBITDA for Q1 FY25 is at Rs. 100 crore compared to Rs. 32 crore in the previous year

HealthCare Global Enterprises posts Q1 FY25 PAT higher at Rs. 12.1 Cr

Our centers are performing as expected or even better

Merck to acquire investigational B-Cell depletion therapy from Curon Biopharmaceutical

CN201 is a next generation CD3xCD19 bispecific antibody that augments and diversifies Merck’s pipeline, with potential applications in B-cell malignancies and autoimmune diseases

Merck inks MoU with Aragen to facilitate supply of equipment and technologies for mAb

This accelerates the clinical-to-commercial process timeline and enables customers to develop the right molecule